



# Resin Y90 for Metastatic Leiomyosarcoma

## Dr. Zachary T. Berman

Associate Clinical Professor of Radiology  
University of California, San Diego  
San Diego, CA



This presentation reflects Dr. Berman's clinical experience with the TriNav<sup>®</sup> Infusion System. Dr. Berman is a consultant for TriSalus<sup>™</sup> Life Sciences and has been compensated for this content. Results are not predictive of outcomes in other cases.




# Case Description

- 72-year-old female with a history of leiomyosarcoma in the liver
- Disease progressed on a systemic therapy
- Treated with resin Y90 microspheres using the TriNav LV
- Delivered TARE using TriNav to increase the T:N ratio


# Angiography

Same contrast injection parameters (1cc/sec for 20cc with 15 sec delay) and same catheter tip placement

Traditional Microcatheter  
MAA Mapping Procedure




TriNav LV  
Radioembolization Procedure



Tumor enhancing angiographically using TriNav LV

# Cone Beam CT

Traditional Microcatheter  
MAA Mapping Procedure




TriNav LV  
Radioembolization Procedure




Increased tumoral enhancement via TriNav LV

# SPECT – Target Tumors

Traditional Microcatheter  
MAA SPECT




TriNav LV  
Y90 SPECT




Significantly better tumor targeting via TriNav LV

# SPECT – Normal Liver

Traditional Microcatheter  
MAA SPECT



TriNav LV  
Y90 SPECT




Significantly less uptake to the normal liver via TriNav LV

# Dosimetry Comparing Dose to Target 5cm Tumor

Tumor 1			Normal Liver					
MAA Estimated Dose Traditional Microcatheter			Y90 Actual Dose TriNav LV			Actual Normal Liver TriNav LV		
D99	26	Gy	D99	91	Gy	D99	0	Gy
D98	26	Gy	D98	94	Gy	D98	0	Gy
D95	30	Gy	D95	97	Gy	D95	0	Gy
D90	34	Gy	D90	101	Gy	D90	0	Gy
D70	45	Gy	D70	107	Gy	D70	0	Gy
D50	54	Gy	D50	115	Gy	D50	0	Gy
D2	79	Gy	D2	135	Gy	D2	136	Gy
D1	79	Gy	D1	136	Gy	D1	144	Gy

2x increase in dose to Tumor 1 when TriNav LV was used, with 0 Gy going to the background liver

# Follow-Up MRI



3-month follow-up MRI shows no residual enhancement and significant shrinkage of the targeted 5cm tumor





## Indications For Use

The TriNav<sup>®</sup> and TriNav<sup>®</sup> LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.<sup>1,2</sup>

## Contraindications

The TriNav<sup>®</sup> and TriNav<sup>®</sup> LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).<sup>1,2</sup>

**Rx Only** For the safe and proper use of TriNav<sup>®</sup> and TriNav<sup>®</sup> LV, refer to their individual Instructions for Use.

This content is sponsored by TriSalus Life Sciences<sup>®</sup>. Results are not predictive of outcomes in other cases.

1. TriSalus<sup>™</sup> TriNav<sup>®</sup> Infusion System, Instructions for Use  
2. TriSalus<sup>™</sup> TriNav<sup>®</sup> LV Infusion System, Instructions for Use

